Changes in the gut microbiota structure and function in rats with doxorubicin-induced heart failureOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared three doxorubicin (DOX) dosing schemes for inducing heart failure (HF) in Sprague Dawley rats, testing which protocol best correlates cardiac dysfunction with gut microbiota (GM) changes.
How was it studied?
DOX was given by tail vein or intraperitoneal injection over six weeks at cumulative doses of 12, 15, or 18 mg per kilogram, using fixed or alternating dosing. Cardiac function was assessed by M-mode echocardiography, NT-proBNP and cardiac troponin I (cTnI) by ELISA, intestinal and heart tissue by H&E and Masson staining, and gut microbiota by 16S rRNA gene sequencing.
What did they find?
Gut microbiota abundance and grouping differed markedly across schemes according to the severity of cardiac dysfunction. Tail vein injection of DOX at a cumulative 18 mg/kg using alternating doses produced the most stable heart failure model, with myocardial injury and microbial composition most consistent with clinical heart failure.
Why it matters
The study identifies tail vein DOX at 4 mg/kg on weeks 1, 3, and 5 and 2 mg/kg on weeks 2, 4, and 6 (18 mg/kg total) as the preferred protocol for studying gut microbiota and heart failure together, giving future research a standardized model.